22 studies found for:    reolysin
Show Display Options
Rank Status Study
1 Recruiting Study of REOLYSIN® in Combination With FOLFIRI and Bevacizumab in FOLFIRI Naive Patients With KRAS Mutant Metastatic Colorectal Cancer
Condition: KRAS Mutant Metastatic Colorectal Cancer
Interventions: Biological: REOLYSIN®;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Fluorouracil (5-FU);   Drug: Bevacizumab
2 Completed Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Placebo
3 Completed Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung
Conditions: Osteosarcoma;   Ewing Sarcoma Family Tumors;   Malignant Fibrous Histiocytoma;   Sarcoma, Synovial;   Fibrosarcoma;   Leiomyosarcoma
Intervention: Biological: REOLYSIN®
4 Recruiting Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer
Condition: Prostate Cancer
Interventions: Drug: Docetaxel, Reolysin and Prednisone;   Drug: Docetaxel and Prednisone
5 Active, not recruiting Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed and Reolysin (and safety run-in);   Drug: Pemetrexed;   Drug: Docetaxel and Reolysin;   Drug: Docetaxel
6 Completed Safety and Efficacy Study of REOLYSIN® in the Treatment of Recurrent Malignant Gliomas
Condition: Malignant Glioma
Intervention: Biological: REOLYSIN®
7 Active, not recruiting Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation
Condition: Carcinoma, Non-small Cell Lung
Interventions: Biological: REOLYSIN®;   Drug: Carboplatin;   Drug: Paclitaxel
8 Recruiting A Study of Reolysin For Patients With Advanced/Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Paclitaxel;   Drug: Reolysin
9 Active, not recruiting Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Folfox plus Bevacizumab and reolysin;   Drug: Folfox plus Bevacizumab
10 Completed A Study of REOLYSIN® in Combination With Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Biological: REOLYSIN;   Drug: Gemcitabine
11 Completed Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: REOLYSIN;   Drug: Carboplatin;   Drug: Paclitaxel
12 Active, not recruiting A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Condition: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Interventions: Biological: REOLYSIN;   Drug: Paclitaxel;   Drug: Carboplatin
13 Completed Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma
Condition: Carcinoma, Squamous Cell of the Head and Neck
Interventions: Biological: REOLYSIN®;   Drug: Carboplatin;   Drug: Paclitaxel
14 Completed
Has Results
Viral Therapy in Treating Patients With Metastatic Melanoma
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Intervention: Biological: wild-type reovirus
15 Completed Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Light Chain Deposition Disease;   Refractory Plasma Cell Myeloma
Interventions: Other: Diagnostic Laboratory Biomarker Analysis;   Biological: Wild-type Reovirus
16 Recruiting Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Carfilzomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Biological: Wild-type Reovirus
17 Completed Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors
Condition: Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Biological: wild-type reovirus;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Other: pharmacological study
18 Recruiting Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Recurrent or Refractory Brain Tumors
Conditions: Astrocytoma;   Childhood Atypical Teratoid/Rhabdoid Tumor;   Glioma;   Recurrent Childhood Anaplastic Oligodendroglioma;   Recurrent Childhood Brain Neoplasm;   Recurrent Childhood Glioblastoma;   Recurrent Childhood Medulloblastoma;   Recurrent Primitive Neuroectodermal Tumor;   Refractory Brain Neoplasm
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Sargramostim;   Biological: Wild-type Reovirus
19 Active, not recruiting Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Wild-type Reovirus
20 Not yet recruiting Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
Interventions: Drug: Bortezomib;   Drug: Dexamethasone;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Wild-type Reovirus

   Previous Page Studies Shown (1-20) Next Page (21-22) Show next page of results    Last Page
Indicates status has not been verified in more than two years